OraliSema™Oral Semaglutide–Research Grade GLP-1 Receptor A

<img src="oral-semaglutide.jpg" alt="GMP-grade Oral Semaglutide for clinical and research use">

Overview

OraliSema™Oral Semaglutide is a research-grade GLP-1 receptor agonist designed for laboratory studies in obesity, type 2 diabetes, and metabolic disorders. As the world’s first clinically validated oral GLP-1 peptide, semaglutide provides researchers with a powerful tool to investigate glucose regulation, appetite control, and weight management mechanisms without the need for injections.

Key Features

Active Ingredient: Semaglutide (GLP-1 receptor agonist)
Formulation: Oral capsule/tablet, research grade
Administration: Once daily, oral delivery
Intended Use: Research programs, laboratory investigation
Supplier: ShiLai™Peptide

Mechanism of Action

Semaglutide acts by mimicking the activity of endogenous GLP-1, resulting in:

Enhanced insulin secretion in response to glucose
Suppressed glucagon release, reducing hepatic glucose output
Delayed gastric emptying, leading to improved satiety
Appetite suppression, supporting weight reduction research models

Research Applications

Obesity and overweight research models
Type 2 diabetes experimental studies
Comparative research of oral vs. injectable GLP-1 agonists
Preclinical metabolic disorder investigations
Pharmaceutical development and formulation studies

Advantages of Oral Formulation

Non-invasive delivery compared to injectable peptides
Improved compliance in long-term study models
Bioavailability enhancement through absorption excipients
Scalable production for bulk research supply

Clinical Data (Reference)

While OraliSema™Oral Semaglutide ( ShiLai™Peptide ) is the marketed oral semaglutide, research-grade oral semaglutide enables broader experimental access:

HbA1c reduction: ~1.0–1.5% in type 2 diabetes studies
Body weight reduction: 4–6 kg over 26–52 weeks
Comparable efficacy to injectable semaglutide in metabolic outcomes

📌 Summary

OraliSema™Oral Semaglutide represents an important advancement in oral peptide research. With its convenient daily oral administration, strong preclinical and clinical data references, and broad research potential, it is positioned to become a cornerstone tool in metabolic and obesity-related investigations.

HbA1c reduction: ~1.0–1.5% in type 2 diabetes studies
Body weight reduction: 4–6 kg over 26–52 weeks
Comparable efficacy to injectable semaglutide in metabolic outcomes